{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:00:03Z","timestamp":1791932403346,"version":"4.3.4"},"reference-count":109,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.vaccine.2022.06.008","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T09:01:39Z","timestamp":1655197299000},"page":"5248-5262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk\/benefit assessment"],"prefix":"10.1016","volume":"40","author":[{"given":"Pedro M","family":"Folegatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Jenkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denny","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emalee","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Gurwith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3-4","key":"10.1016\/j.vaccine.2022.06.008_b0005","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0264-410X(02)00449-8","article-title":"The brighton collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI)","volume":"21","author":"Bonhoeffer","year":"2002","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.008_b0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.vaccine.2014.09.035","article-title":"The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)","volume":"33","author":"Chen","year":"2015","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.008_b0015","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.vaccine.2022.06.008_b0020","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/infdis\/jiq114","article-title":"Step study protocol team. An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study)","volume":"203","author":"Fitzgerald","year":"2011","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2022.06.008_b0025","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1086\/587993","article-title":"Merck V520\u2013016 study group. safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag\/pol\/nef vaccine in healthy adults","volume":"46","author":"Priddy","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"9653","key":"10.1016\/j.vaccine.2022.06.008_b0030","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Step study protocol team. efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.vaccine.2022.06.008_b0035","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine","volume":"369","author":"Hammer","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2022.06.008_b0040","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1080\/21645515.2017.1342021","article-title":"Open-label phase I clinical trial of Ad5-EBOV in africans in china","volume":"13","author":"Wu","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"10249","key":"10.1016\/j.vaccine.2022.06.008_b0045","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.008_b0050","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"EBOVAC2 EBL2001 study group. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"Pollard","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"19","key":"10.1016\/j.vaccine.2022.06.008_b0055","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim Results of a Phase 1\u20132a Trial of Ad26.COV2.S Covid-19 Vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"10275","key":"10.1016\/j.vaccine.2022.06.008_b0060","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.008_b0065","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jir850","article-title":"Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector","volume":"205","author":"O\u2019Hara","year":"2012","journal-title":"J Infect Dis"},{"issue":"23","key":"10.1016\/j.vaccine.2022.06.008_b0070","doi-asserted-by":"crossref","first-page":"11603","DOI":"10.1128\/JVI.75.23.11603-11613.2001","article-title":"Replication-Defective Vector Based on a Chimpanzee Adenovirus","volume":"75","author":"Farina","year":"2001","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.06.008_b0075","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.4049\/jimmunol.170.3.1416","article-title":"A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag","volume":"170","author":"Fitzgerald","year":"2003","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.008_b0080","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.4049\/jimmunol.103.5.1089","article-title":"Serologic classification of chimpanzee adenoviruses by hemagglutination and hemagglutination inhibition","volume":"103","author":"Hillis","year":"1969","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2022.06.008_b0085","doi-asserted-by":"crossref","unstructured":"Dicks, M.D., et al., A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One, 2012. 7(7): p. e40385.","DOI":"10.1371\/journal.pone.0040385"},{"key":"10.1016\/j.vaccine.2022.06.008_b0090","article-title":"T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","author":"Ewer","year":"2020","journal-title":"Nat Med"},{"issue":"37","key":"10.1016\/j.vaccine.2022.06.008_b0095","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1016\/j.vaccine.2019.07.095","article-title":"Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice","volume":"37","author":"Asthagiri Arunkumar","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.008_b0100","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.3389\/fimmu.2019.02005","article-title":"Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge","volume":"10","author":"McMahon","year":"2019","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.008_b0105","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01787-20","article-title":"Vaccines That Reduce Viral Shedding Do Not Prevent Transmission of H1N1 Pandemic 2009 Swine Influenza A Virus Infection to Unvaccinated Pigs","volume":"95","author":"Everett","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.06.008_b0110","doi-asserted-by":"crossref","unstructured":"van Doremalen N, et al., A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters. PLoS Negl Trop Dis., 2019. 13(6): p. e0007462.","DOI":"10.1371\/journal.pntd.0007462"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.008_b0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-04859-5","article-title":"Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors","volume":"9","author":"L\u00f3pez-Camacho","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.008_b0120","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-021-00291-x","article-title":"ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge","volume":"6","author":"Fischer","year":"2021","journal-title":"npj Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2022.06.008_b0125","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3390\/vaccines8020241","article-title":"A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector","volume":"8","author":"Sebastian","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2022.06.008_b0130","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-017-0029-1","article-title":"Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model","volume":"2","author":"Munster","year":"2017","journal-title":"npj Vaccines"},{"issue":"7830","key":"10.1016\/j.vaccine.2022.06.008_b0135","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.vaccine.2022.06.008_b0140","first-page":"243","article-title":"A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice","volume":"2","author":"Silva-Cayetano","year":"2021","journal-title":"Med (N Y)"},{"key":"10.1016\/j.vaccine.2022.06.008_b0145","article-title":"Intranasal ChAdOx1 nCoV-19\/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques","volume":"11","author":"van Doremalen","year":"2021","journal-title":"bioRxiv [Preprint]"},{"issue":"3","key":"10.1016\/j.vaccine.2022.06.008_b0150","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3390\/vaccines8030346","article-title":"Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+ T Cell Immunity to Bluetongue Virus","volume":"8","author":"Utrilla-Trigo","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2022.06.008_b0155","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/1743-422X-10-349","article-title":"Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice","volume":"10","author":"Warimwe","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2022.06.008_b0160","doi-asserted-by":"crossref","first-page":"20617","DOI":"10.1038\/srep20617","article-title":"Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever","volume":"6","author":"Warimwe","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2022.06.008_b0165","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41541-019-0138-0","article-title":"Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats","volume":"4","author":"Stedman","year":"2019","journal-title":"npj Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.008_b0170","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3390\/v11040322","article-title":"Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus","volume":"11","author":"L\u00f3pez-Camacho","year":"2019","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.008_b0175","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3390\/pathogens8040231","article-title":"A Single and Un-Adjuvanted Dose of a Chimpanzee Adenovirus-Vectored Vaccine against Chikungunya Virus Fully Protects Mice from Lethal Disease","volume":"8","author":"Kroon Campos","year":"2019","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2022.06.008_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00923","article-title":"Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB\/c Mice","volume":"10","author":"Kilpel\u00e4inen","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.06.008_b0185","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/vaccines7030078","article-title":"Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB\/c Mice","volume":"7","author":"Kilpel\u00e4inen","year":"2019","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.008_b0190","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55014-z","article-title":"A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins","volume":"9","author":"Hancock","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2022.06.008_b0195","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2017.10.079","article-title":"The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes","volume":"36","author":"von Delft","year":"2018","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2022.06.008_b0200","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/hep.30894","article-title":"Use of an Outbred Rat Hepacivirus Challenge Model for Design and Evaluation of Efficacy of Different Immunization Strategies for Hepatitis C Virus","volume":"71","author":"Atcheson","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.vaccine.2022.06.008_b0205","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/vaccines8020184","article-title":"The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBV","volume":"8","author":"Chinnakannan","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.vaccine.2022.06.008_b0210","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2022.06.008_b0215","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ebiom.2018.02.011","article-title":"Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults","volume":"29","author":"Coughlan","year":"2018","journal-title":"EBioMedicine"},{"issue":"30","key":"10.1016\/j.vaccine.2022.06.008_b0220","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2017.05.032","article-title":"ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice","volume":"35","author":"Alharbi","year":"2017","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2022.06.008_b0225","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aba8399","article-title":"A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques","volume":"6","author":"van Doremalen","year":"2020","journal-title":"Sci Adv"},{"issue":"10249","key":"10.1016\/j.vaccine.2022.06.008_b0230","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.008_b0235","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.vaccine.2019.10.102","article-title":"A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults","volume":"38","author":"Wilkie","year":"2020","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.008_b0240","doi-asserted-by":"crossref","first-page":"e000928","DOI":"10.1136\/jitc-2020-000928","article-title":"Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial","volume":"8","author":"Cappuccini","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.008_b0245","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24906-y","article-title":"A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial","volume":"12","author":"Folegatti","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.008_b0250","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1021\/acscentsci.1c00080","article-title":"Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19\/AZD1222 Vaccine","volume":"7","author":"Watanabe","year":"2021","journal-title":"ACS Cent Sci"},{"issue":"10249","key":"10.1016\/j.vaccine.2022.06.008_b0255","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"issue":"10269","key":"10.1016\/j.vaccine.2022.06.008_b0260","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"10267","key":"10.1016\/j.vaccine.2022.06.008_b0265","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.06.008_b0270","unstructured":"AstraZeneca, 2021. Two billion doses of AstraZeneca\u2019s COVID-19 vaccine supplied to countries across the world less than 12 months after first approval. https:\/\/www.astrazeneca.com\/content\/astraz\/media-centre\/press-releases\/2021\/two-billion-doses-of-astrazenecas-covid-19-vaccine-supplied-to-countries-across-the-world-less-than-12-months-after-first-approval.html."},{"issue":"22","key":"10.1016\/j.vaccine.2022.06.008_b0275","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.vaccine.2022.06.008_b0280","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.008_b0285","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/jth.15572","article-title":"Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources","volume":"20","author":"Greinacher","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"23","key":"10.1016\/j.vaccine.2022.06.008_b0290","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.06.008_b0295","doi-asserted-by":"crossref","unstructured":"Goldman M, Hermans C., Thrombotic thrombocytopenia associated with COVID-19 infection or vaccination: Possible paths to platelet factor 4 autoimmunity. PLoS Med, 2021. 18(5): p. e1003648.","DOI":"10.1371\/journal.pmed.1003648"},{"key":"10.1016\/j.vaccine.2022.06.008_b0300","unstructured":"WHO, 2021. Global Advisory Committee on Vaccine Safety (Gacvs) Review of Latest Evidence of Rare Adverse Blood Coagulation Events with Astrazeneca Covid-19 Vaccine (VAXZEVRIA AND COVISHIELD). healthalert.whofreebasics.org\/locale\/en\/?next=%2Fsections%2Fnews%2Fglobal-advisory-committee-vaccine-safety-gacvs-review-latest-evidence-rare-adverse-blood-coagulation-events-astrazeneca-covid-19-vaccine-vaxzevria-and-covishield%2F."},{"key":"10.1016\/j.vaccine.2022.06.008_b0305","unstructured":"European Medicines Agency, 2021. COVID-19 vaccine safety update. https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-14-july-2021_en.pdf."},{"key":"10.1016\/j.vaccine.2022.06.008_b0310","unstructured":"European Medicines Agency, 2021. Vaxzevria, COVID-19 Vaccine (ChAdOx1-S (recombinant). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf."},{"key":"10.1016\/j.vaccine.2022.06.008_b0315","unstructured":"AstraZeneca, 2021. European Union Risk Management Plan (EU RMP) for Vaxzevria (ChAdOx1-S [Recombinant]). 3(3). vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-risk-management-plan_en.pdf (europa.eu)."},{"key":"10.1016\/j.vaccine.2022.06.008_b0320","doi-asserted-by":"crossref","unstructured":"Potteg\u00e5rd A., et al., Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study. BMJ, 2021. 373: n1114.","DOI":"10.1136\/bmj.n1114"},{"issue":"7","key":"10.1016\/j.vaccine.2022.06.008_b0325","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41591-021-01408-4","article-title":"First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland","volume":"27","author":"Simpson","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2022.06.008_b0330","doi-asserted-by":"crossref","unstructured":"Hippisley-Cox J, et al., Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ, 2021. 374: n1931.","DOI":"10.1136\/bmj.n1931"},{"key":"10.1016\/j.vaccine.2022.06.008_b0335","doi-asserted-by":"crossref","unstructured":"Schoch, C.L., et al., NCBI Taxonomy: a comprehensive update on curation, resources and tools. Database (Oxford), 2020. baaa062.","DOI":"10.1093\/database\/baaa062"},{"issue":"3","key":"10.1016\/j.vaccine.2022.06.008_b0340","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/v8030066","article-title":"Linking Virus Genomes with Host Taxonomy","volume":"8","author":"Mihara","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2022.06.008_b0345","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ecoinf.2014.08.005","article-title":"Global biotic interactions: An open infrastructure to share and analyze species-interaction datasets","volume":"24","author":"Poelen","year":"2014","journal-title":"Ecol Inf"},{"key":"10.1016\/j.vaccine.2022.06.008_b0350","doi-asserted-by":"crossref","unstructured":"Saravanan, C., et al., Chapter 10 - Nonhuman Primate Diseases of Relevance in Drug Development ands their Impact on the Interpretation of Study Findings, in The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment, J. Bluemel, et al., Editors. 2015, Academic Press: San Diego. p. 187-213.","DOI":"10.1016\/B978-0-12-417144-2.00010-X"},{"key":"10.1016\/j.vaccine.2022.06.008_b0355","first-page":"1","article-title":"Viral Diseases of Nonhuman Primates","author":"Wachtman","year":"2012","journal-title":"Nonhuman Primates in Biomedical Research"},{"key":"10.1016\/j.vaccine.2022.06.008_b0360","doi-asserted-by":"crossref","unstructured":"Roy, S., et al., Isolation and Characterization of Adenoviruses Persistently Shed from the Gastrointestinal Tract of Non-Human Primates. PLOS Pathogens, 2009. 5(7): p. e1000503.","DOI":"10.1371\/journal.ppat.1000503"},{"issue":"2","key":"10.1016\/j.vaccine.2022.06.008_b0365","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes & Diseases"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.008_b0370","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1634\/theoncologist.7-1-46","article-title":"Adenoviral Gene Therapy","volume":"7","author":"Vorburger","year":"2002","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.vaccine.2022.06.008_b0375","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1128\/JVI.73.7.6141-6146.1999","article-title":"Frequency and Stability of Chromosomal Integration of Adenovirus Vectors","volume":"73","author":"Harui","year":"1999","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2022.06.008_b0380","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3201\/eid1210.060078","article-title":"Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa","volume":"12","author":"Xiang","year":"2006","journal-title":"Emerg Infect Dis"},{"issue":"20","key":"10.1016\/j.vaccine.2022.06.008_b0385","doi-asserted-by":"crossref","first-page":"10774","DOI":"10.1128\/JVI.00810-11","article-title":"Novel adenoviruses in wild primates: a high level of genetic diversity and evidence of zoonotic transmissions","volume":"85","author":"Wevers","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.06.008_b0390","doi-asserted-by":"crossref","unstructured":"Chen, E.C., et al., Cross-Species Transmission of a Novel Adenovirus Associated with a Fulminant Pneumonia Outbreak in a New World Monkey Colony. PLOS Pathogens, 2011. 7(7): p. e1002155.","DOI":"10.1371\/journal.ppat.1002155"},{"issue":"10","key":"10.1016\/j.vaccine.2022.06.008_b0395","doi-asserted-by":"crossref","first-page":"7909","DOI":"10.1128\/JVI.72.10.7909-7915.1998","article-title":"The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F","volume":"72","author":"Roelvink","year":"1998","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.008_b0400","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1099\/0022-1317-83-1-151","article-title":"Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor","volume":"83","author":"Cohen","year":"2002","journal-title":"J Gen Virol"},{"issue":"19","key":"10.1016\/j.vaccine.2022.06.008_b0405","doi-asserted-by":"crossref","first-page":"12125","DOI":"10.1128\/JVI.79.19.12125-12131.2005","article-title":"Adenovirus receptors","volume":"79","author":"Zhang","year":"2005","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.008_b0410","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1473-3099(14)70020-9","article-title":"HVTN 503\/Phambili study team. Recombinant adenovirus type 5 HIV gag\/pol\/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503\/Phambili study","volume":"14","author":"Gray","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.008_b0415","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1055\/s-0036-1584923","article-title":"Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention","volume":"37","author":"Lynch","year":"2016","journal-title":"Seminars in respiratory and critical care medicine"},{"issue":"1-3","key":"10.1016\/j.vaccine.2022.06.008_b0420","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.2741\/1607","article-title":"Adenovirus vectors deleted for genes essential for viral DNA replication","volume":"10","author":"Schaack","year":"2005","journal-title":"Front Biosci"},{"issue":"8","key":"10.1016\/j.vaccine.2022.06.008_b0425","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3390\/v2081681","article-title":"Adenoviral producer cells","volume":"2","author":"Kovesdi","year":"2010","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.vaccine.2022.06.008_b0430","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1473-3099(20)30160-2","article-title":"Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial","volume":"20","author":"Folegatti","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"10267","key":"10.1016\/j.vaccine.2022.06.008_b0435","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"The Lancet"},{"issue":"10282","key":"10.1016\/j.vaccine.2022.06.008_b0440","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial","volume":"397","author":"Emary","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.008_b0445","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-52730-4","article-title":"Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels","volume":"9","author":"Alharbi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2022.06.008_b0450","unstructured":"Almuqrin A, et al.. SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of."},{"issue":"8","key":"10.1016\/j.vaccine.2022.06.008_b0455","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.cell.2021.02.033","article-title":"Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera","volume":"184","author":"Supasa","year":"2021","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.vaccine.2022.06.008_b0460","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","article-title":"Antibody evasion by the P.1 strain of SARS-CoV-2","volume":"184","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2022.06.008_b0465","article-title":"Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses","author":"Barrett","year":"2020","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.vaccine.2022.06.008_b0470","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(21)00103-X","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2\/3 clinical trial","volume":"8","author":"Frater","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.vaccine.2022.06.008_b0475","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.reprotox.2021.07.010","article-title":"Developmental and reproductive safety of AZD1222 (ChAdOx1 nCoV-19) in mice","volume":"104","author":"Stebbings","year":"2021","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.vaccine.2022.06.008_b0480","unstructured":"Agency, M.a.H.p.R., Public Assessment Report for AstraZeneca COVID-19 vaccine, D.o.H.a.S.C. (DHSC), Editor. 2021, UK Government."},{"key":"10.1016\/j.vaccine.2022.06.008_b0485","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41541-020-00221-3","article-title":"Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19","volume":"5","author":"Graham","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2022.06.008_b0490","unstructured":"Vaxveria, 2021. COVID-19 vaccine weekly safety report - 28-10-2021. https:\/\/www.tga.gov.au\/periodic\/covid-19-vaccine-weekly-safety-report\/current."},{"key":"10.1016\/j.vaccine.2022.06.008_b0495","unstructured":"European Medicines Agency, 2021. Vaxzevria: EMA advises against use in people with history of capillary leak syndrome. https:\/\/www.ema.europa.eu\/en\/news\/vaxzevria-ema-advises-against-use-people-history-capillary-leak-syndrome."},{"key":"10.1016\/j.vaccine.2022.06.008_b0500","unstructured":"Melbourne Vaccine Education Centre, 2021. Update advice regarding capillary leak syndrome. https:\/\/mvec.mcri.edu.au\/updated-advice-regarding-capillary-leak-syndrome\/."},{"key":"10.1016\/j.vaccine.2022.06.008_b0505","unstructured":"Vaxveria, 2021. VAXZEVRIA\u2122\/COVID-19 Vaccine AstraZeneca: Risk of thrombocytopenia (including immune thrombocytopenia) with or without associated bleeding. https:\/\/www.ema.europa.eu\/en\/documents\/dhpc\/direct-healthcare-professional-communication-dhpc-vaxzevria-previously-covid-19-vaccine-astrazeneca_en-2.pdf."},{"issue":"10300","key":"10.1016\/j.vaccine.2022.06.008_b0510","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(21)01693-7","article-title":"Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis","volume":"398","author":"Bhuyan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.06.008_b0515","doi-asserted-by":"crossref","first-page":"100639","DOI":"10.1016\/j.eclinm.2020.100639","article-title":"Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis","volume":"29-30","author":"Malas","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2022.06.008_b0520","first-page":"101061","article-title":"Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases","volume":"39","author":"Taquet","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.06.008_b0525","unstructured":"\u201cThrombosis with Thrombocytopenia SYNDROME (Also Termed Vaccine-Induced Thrombotic Thrombocytopenia).\u201d Learning, www.hematology.org\/covid-19\/vaccine-induced-immune-thrombotic-thrombocytopenia."},{"key":"10.1016\/j.vaccine.2022.06.008_b0530","unstructured":"International Society on Thrombosis and Haemostasis, 2021. The ISTH releases interim guidance on vaccine-induced immune thrombotic thrombocytopenia (VITT). https:\/\/www.isth.org\/news\/561406\/The-ISTH-Releases-Interim-Guidance-on-Vaccine-Induced-Immune-Thrombotic-Thrombocytopenia-VITT-.htm."},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.008_b0535","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/jth.15572","article-title":"Vaccine\u2010induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources","volume":"20","author":"Greinacher","year":"2022","journal-title":"J of Thrombosis Haemost"},{"key":"10.1016\/j.vaccine.2022.06.008_b0540","unstructured":"European Medicines Agency, 2021. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 September 2021. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-27-30-september-2021."},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.008_b0545","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S2214-109X(21)00545-3","article-title":"Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination","volume":"10","author":"Soboleva","year":"2022","journal-title":"Lancet Glob Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22007551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22007551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:17:22Z","timestamp":1759403842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22007551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":109,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0264410X22007551"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.008","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk\/benefit assessment","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}